Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
July 6, 2023
- Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
July 6, 2023
- Drug Pricing Rules to Be Applied to Novartis’ Gene Therapy Luxturna
July 6, 2023
- 5 FPMAJ-Affiliated Bodies Petition Expanded Coverage, Eased Criteria for Essential Drug Rule
July 6, 2023
- Hideo Hashimoto Named MOF Budget Examiner for Healthcare
July 5, 2023
- MHLW to Launch Pharma Affairs Study Group July 10, Drug Loss Up for Debate
July 4, 2023
- MHLW Panel OKs 282 More Health Damage Claims for COVID Vaccines
July 4, 2023
- Hiroyuki Uchiyama Tapped as Assistant Vice Minister for Pharma Promotion
July 3, 2023
- LDP Bigwigs Launch Study Group on Drug Discovery to Spur Innovation
July 3, 2023
- Average Annual Pay for PMDA Staffers at 7.71 Million Yen in FY2022
July 3, 2023
- MHLW Reports 3 New Cases of Inadvertent Use of Xocova in Pregnant Women
July 3, 2023
- Study Group of Lawmakers, Industry Urges Earlier Launch of Genome Analysis Project Organ
July 3, 2023
- MHLW Expert Panel’s Report Serves as Starting Line for Reform: Asst. Vice Minister
June 30, 2023
- Japan to Revise Generic Use Target to Value-Based Figure
June 30, 2023
- MHLW to Run Pilot Sale of Emergency Contraceptives without Prescription
June 29, 2023
- Japan Mulls Narrowing Down COVID-19 Jabs to Pfizer, but Some Lawmakers Are Skeptical
June 29, 2023
- PMDA Reviewing Anaphylaxis Risk for Xocova
June 29, 2023
- MHLW Shuffles Senior Bureaucrats, Jo Tapped as Chief of Pharma Bureau
June 28, 2023
- After Years of Debates, Wholesalers’ Negative Primary Margins Remain a Problem
June 28, 2023
- SCARDA, CEPI Ink Pact to Beef Up Collab for Vaccine Development
June 28, 2023
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…